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Abstract
In female mammals, including humans, deviations from normal androgenic or estrogenic exposure
during fetal development are detrimental to subsequent adult ovarian function. Androgen
deficiency, without accompanying estrogen deficit, has little apparent impact on ovarian
development. Fetal estrogen deficiency, on the other hand, results in impaired oocyte and follicle
development, immature and abnormal adult ovaries, and excessive ovarian stimulation from
endogenous gonadotropins ultimately generating hemorrhagic follicles. Complete estrogen
deficiency lasting into adulthood results in partial ovarian masculinization. Fetal androgen excess,
on the other hand, mediated either by direct androgen action or following androgen aromatization
to estrogen, reprograms ovarian development and reproductive neuroendocrinology to mimic that
found in women with polycystic ovary syndrome: enlarged, polyfollicular, hyperandrogenic,
anovulatory ovaries with accompanying LH hypersecretion. Oocyte developmental competence is
also compromised. Insulin is implicated in the mechanism of both anovulation and deficient oocyte
development. Fetal estrogen excess induces somewhat similar disruption of adult ovarian function
to fetal androgen excess. Understanding the quality of the fetal female sex steroid hormone
environment is thus becoming increasingly important in improving our knowledge of mechanisms
underlying a variety of female reproductive pathologies.
Introduction
Impaired fetal growth and subsequent adult cardiovascu-
lar disease [1] provide the best known example of fetal
programming of adult pathology. Fetal programming is
triggered when a stimulus or insult occurs at a gestational
age critical for target organ differentiation, growth or
development and induces permanent changes in organ
size, structure or function. Developmental insults to the
fetus, such as low calorie or low protein maternal diets,
program for hypertension, insulin resistance, type 2 dia-
betes and obesity in adulthood [2]. Fetal glucocorticoid
excess also programs many of the same adult traits
induced by low calorie and low protein maternal diets,
and has been proposed as the common physiological
mechanism translating maternal environmental factors
into impaired fetal growth and fetal programming of
organ function [3].
Steroid hormone excess, including glucocorticoid and sex
hormone excess during fetal life, is well known to induce
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permanent alterations in adult female phenotype. For
example, fetal androgen excess induces female uro-genital
virilization along with masculinized behavior, and neural
anatomy and function [4], while fetal estrogen excess
results in female reproductive tract abnormalities, includ-
ing clear cell adenocarcinoma of the vagina and cervix, as
well as increased risk of breast cancer [5]. Less is known,
however, about fetal progestin excess which can mimic
androgen excess in its fetal programming outcomes [6,7].
Steroid hormones mediate their classical or genomic
actions by binding to nuclear receptors and engaging a
variety of molecular chaperones permitting ultimate bind-
ing of the entire complex to steroid response elements on
promoters of target genes [8]. Nonclassical or non-
genomic actions of steroids, including rapid changes in
cytoplasmic protein function without steroid-receptor
complex binding to DNA, are mediated by cell membrane
receptors such as GPR30, a G-protein coupled protein
mediating rapid estrogen action (estrogen membrane
receptor: [9]; androgen membrane receptor: [10]; proges-
terone membrane receptor: [11]). Whether prenatal ster-
oid hormone programming of postnatal ovarian function
involves either or both classical and non-classical action is
not known. Studies to date have assumed a classical or
genomic action.
It is certainly becoming clear that exposing female fetuses
to androgen excess results in enlarged adult ovaries that
are polyfollicular, anovulatory and hyperandrogenic, and
resemble those found in women with polycystic ovary
syndrome (PCOS: monkeys: [12]; sheep: [13]). Fetal
estrogen excess, on the other hand, diminishes ovarian
size and function while increasing anovulation in adult-
hood [14-16]. This mini-review will focus on the role of
fetal androgens and estrogens in determining postnatal
ovarian phenotype (summarized in Table 1), and the rel-
evance of such fetal programming to reproductive health
in women.
Fetal androgen deficiency
Within the ovary, androgens are synthesized mainly
within theca cells and the ovarian stroma, while mural
granulosa cells convert theca-cell derived androstenedi-
one into testosterone and dihydrotestosterone (DHT).
Since androgen receptors are expressed in the fetal ovary
[17] and in oocytes, granulosa and theca cells, and ovar-
ian stroma in the mature, adult ovary [18-20], androgen
action can effect many components of ovarian develop-
ment and cyclical function [21].
Discrete experimental induction of fetal androgen defi-
ciency induced by the administration of flutamide to
pregnant rhesus monkeys during either early or late gesta-
tion fails to alter age at menarche and at first ovulation in
exposed female fetuses [22]. Fetal deficiencies in female
androgen biosynthesis induced by congenital defect or
experimentally induced knockout of mitochondrial ster-
oidogenic acute regulatory protein (StAR; [23]), and ster-
oid biosynthetic enzyme, P450c17 [24,25], however,
produce obvious defects in ovarian function, but andro-
gen deficiencies also persist into postnatal life. Androgen
deficiencies in adult female StAR knockout mice result in
Table 1: Summary of major reproductive dysfunction or anomalies associated with fetal deficiency or excess of androgen or estrogen
Major reproductive dysfunction/anomaly Fetal deficiency of: Fetal excess of:
Androgenb Estrogena Androgen Estrogen
Ovarian
Reduced ovulatory frequency + [29] + [45] + [12, 50–56] + [15, 76, 80, 81]
Reduced follicle number ? + [33, 44] + [69] + [14, 77]
Reduced ovarian response to FSH + [29] + [42, 43] + [69] ?
Excessive, endogeneous hypergonadotropic-
inducing hemorrhagic follicles
- + [38, 45] - -
Ovarian hyperandrogenism - + [38] + [49, 53] + [77, 79]
Polycystic ovaries ? - + [13, 52, 57] ?
Impaired oocyte developmental competence ? ? + [28, 69, 70] ?
Partial masculinization of the ovary - + [47, 48] - -
Premature ovarian senescence ? ? + [50–52] ?
Neuroendocrine
Increased LH levels ? + [24, 38, 45] + [12, 53, 56, 60] ?
Increased FSH levels ? + [24, 45] - ?
De-sensitized estradiol/progesterone negative 
feedback on LH
? ? + [49, 53–56, 58–60] ?
Increased gonadotrope LH sensitivity to GnRH ? ? + [49] ?
a : as discussed in the text, many instances of fetal androgen and estrogen deficiencies persist into adult life and partially confound assessments of 
the precise causes of the reproductive abnormalities found.
b : abnormalities summarized in this table reflect studies in which there were no concomitant deficiencies in estrogenReproductive Biology and Endocrinology 2006, 4:17 http://www.rbej.com/content/4/1/17
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undectectable circulating levels of testosterone, extremely
low levels of progesterone and corticosterone, and a
poorly developed reproductive tract, indicative of hypoes-
trogenism [23]. Not surprisingly, the ovaries fail to show
major follicle development or the presence of corpora
lutea, but they do become enlarged due to hypertrophy of
the stroma under endogenous hypergonadotropic over-
stimulation. Similar to the androgen deficiency produced
by defective or absent StAR, women deficient in the bio-
synthetic enzyme, P450c17, show marked impairment in
androgenic, estrogenic and glucocorticoid biosynthesis
[26], as well as anovulatory, hypergonadotropic hypogo-
nadism. The ovaries are devoid of major follicle develop-
ment, but experimentally-induced gonadotropic ovarian
hyperstimulation for in vitro fertilization (IVF) induces the
growth of dominant follicles that yield fertilizable oocytes
at retrieval. None of the fertilized oocytes, however,
progress beyond the 7-cell embryonic stage [24], and fail
to reach developmental stages when they are completely
dependent on the embryonic genome [27]. Such impaired
embryonic developmental competence probably reflects a
sub-optimal intra-follicular estrogenic environment due
to deficient production of androgen precursors for estro-
gen biosynthesis by mural granulosa cells [28].
When life-long androgen deficiencies do not concomi-
tantly result in fetal estrogen deficiencies, such as in
androgen receptor knockout (ARKO) female mice, there
are only subtle impairments in adult ovarian function
(Table 1). While ovarian follicle counts are similar to
those in wild type mice, ARKO mice have fewer estrus
cycles, smaller litter sizes, yield fewer oocytes upon gona-
dotropic hyperstimulation, and exhibit a diminished
granulosa cell layer within follicles and smaller-sized cor-
pora lutea [29]. Androgens may thus play important roles
in the adult ovary supporting ovarian follicle and oocyte
maturation, as found by Bondy and colleagues [30-32]
when they treated adult female rhesus monkeys with tes-
tosterone. Unlike estrogens, however, androgens are not
apparently required during fetal life for normal ovarian
development.
Fetal estrogen deficiency
Studies repeatedly implicate a key role for fetal estrogen in
the normal development of ovarian morphology and
function (Table 1). Exposure of fetal female baboons to a
hypoestrogenic environment, by treating their pregnant
mothers with an aromatase inhibitor during mid- to late
gestation, halves the numbers of primordial follicles
found in fetal ovaries at late gestation [33], and drastically
reduces the numbers of oocyte-granulosa cell microvilli
[34] that are essential for oocyte nutrition and oocyte-
granulosa cell intra-follicular communication [35]. Con-
comitant treatment of pregnant mothers with aromatase
inhibitor and estradiol prevents the late gestation ovarian
consequences induced by inhibitor treatment, alone, and
specifically implicates estradiol in the normal develop-
ment of ovarian follicles [33,34]. Whether these fetal
ovarian deficiencies translate into abnormal adult ovarian
function is not yet known.
Estrogen deficiencies that are manifest beyond fetal life, as
found in estrogen receptor or aromatase knockout female
mice, while confounded in terms of manifesting specific
fetal programming effects, provide additional insight into
discrete components of estrogen action involved in ovar-
ian development and function. ERα receptor expression is
found in theca cells and ovarian stroma, while ERβ recep-
tor is located in granulosa cells of growing follicles
[36,37]. Given their differing ovarian locations, it is not
surprising that the inability of estrogen to bind to the ERα
receptor (ERKO) produces different abnormalities than
those found in ERβ receptor knockout (BERKO) mice.
ERKO female mice exhibit an ovarian phenotype of
chronic anovulation, cystic and hemorrhagic follicles,
absent corpora lutea, interstitial/stromal hyperplasia, and
elevated plasma estradiol and testosterone levels in the
presence of luteinizing hormone (LH) excess [38]. Since
gonadotropin-releasing hormone (GnRH) analogue treat-
ment normalizes LH levels and ovarian morphology in
ERKO mice, and gonadotropin ovarian hyperstimulation
results in ovulation, many of the ovarian abnormalities
appear secondary to the loss of ERα-mediated negative
feedback regulation of LH at the hypothalamus-pituitary
level [39,40]. In contrast to ERKO mice, BERKO animals
are ovulatory, circulating LH levels are normal, and
females give birth to live young, albeit with reduced num-
bers of corpora lutea and smaller litter sizes [41]. The
ovarian phenotype in BERKO mice thus reflects impair-
ments in estrogen action within the ovary related to folli-
cle maturation and differentiation [42,43]. In aromatase
knockout (ArKO) mice, devoid of estrogen synthesis
rather than estrogen action, the numbers of primordial
follicles are reduced apparently due to their lack of forma-
tion from fetal germ cell nests and to precocious activa-
tion of follicle growth from the primordial pool [44]. In
the complete absence of estrogen, ArKO females are ano-
vulatory, folliculogenesis is arrested at the antral stage,
and the ovaries manifest hemorrhagic cysts due to endog-
enous hypergonadotropism [45].
Unexpectedly, the adult ovarian phenotype of double
estrogen receptor knockout mice (αβERKO) is masculi-
nized, with a concomitant reduction in oocyte number.
An absence of estrogen action was previously considered
relatively unimportant in female mammalian differentia-
tion [4], except for differentiation of the brain [46]. Struc-
tures resembling testicular seminferous tubules, however,
are present in the ovaries of αβERKO mice, the ovaries
express two genes involved in Sertoli cell differentiation,Reproductive Biology and Endocrinology 2006, 4:17 http://www.rbej.com/content/4/1/17
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sulfated glycoprotein-2 and Sox9, and an additional gene
involved in androgen biosynthesis, 17β-Hsd-3, that is nor-
mally expressed only in Leydig cells [39,47]. There is even
more dramatic masculinization of the ovaries of ArKO
mice. Postpubertally, ArKO ovaries possess Sertoli and
Leydig cells, express Sox9, and over-express genes coding
for androgen biosynthesis [48]. Since both αβERKO and
ArKO mice possess female and not male reproductive
tracts, and follicles contain oocytes and not male-like
germ cells, estrogen appears to play a key role in maintain-
ing adult ovarian somatic cell phenotype [48] rather than
in differentiating a fetal ovary. In humans, in comparison,
while congenital aromatase deficiency leads to hyperan-
drogenic, multicystic ovarian phenotypes, and elevated
LH and FSH levels are normalized by exogenous estrogen
treatment [24], the ovaries of such women have yet to be
examined for the presence of testicular structures and gene
expression.
Fetal androgen excess
In contrast to fetal androgen deficiency, fetal androgen
excess has striking consequences for adult ovarian func-
tion (Table 1, [49]). Female rhesus monkeys [12], sheep
[50-52], mice [53] and rats [54-56] exposed, in utero, to
excessive levels of either testosterone or its non-aromatiz-
able metabolite, dihydrotestosterone, exhibit intermittent
or absent ovulatory cycles in adulthood. The ovaries are
also enlarged and polyfollicular in prenatally androgen-
ized monkeys and sheep [57,13], and such females have
been shown to be hyperandrogenic in prenatally andro-
genized monkeys and mice [49,53,57]. Hypothalamic-
pituitary regulation of LH release is deranged in prenatally
Summary of the fetal origins hypothesis for androgen excess programming of polycystic ovary syndrome (PCOS) in the prena- tally androgenized female rhesus monkey, a nonhuman primate model for PCOS in women Figure 1
Summary of the fetal origins hypothesis for androgen excess programming of polycystic ovary syndrome (PCOS) in the prena-
tally androgenized female rhesus monkey, a nonhuman primate model for PCOS in women.
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androgen-treated females from all four species resulting in
LH hypersecretion, probably driven by enhanced fre-
quency or amplitude of hypothalamic GnRH release that,
in turn, may be due to desensitization of the hypothala-
mus to negative feedback of estradiol and progesterone
[49,53,56,58-60] and/or increased pituitary sensitivity to
GnRH [49]. These androgen excess phenotypes are
remarkably similar to those of women with polycystic
ovary syndrome (PCOS), suggesting a fetal origin for this
highly prevalent women's health disorder [61].
Administration of flutamide, an antagonist of the classical
androgen receptor, to adult prenatally androgenized
female mice, normalizes both hypothalamic function and
cyclicity, suggestive of a role for adult hyperandrogenism
in these disruptions [53]. In addition to altered androgen
action, impaired insulin action may also contribute to
fetal androgen excess programming of anovulation since
treatment of adult, prenatally androgenized female mon-
keys with pioglitazone, a PPARgamma receptor ligand
and insulin sensitizer, normalizes menstrual cycles [62].
In this regard, it is interesting to note that fetal androgen
excess programs for metabolic dysfunction, including
insulin resistance (monkeys: [49,63]; sheep: [64]) and
abdominal obesity (monkeys: [65]), additional symp-
toms commonly found in women with PCOS, as illus-
trated in the fetal origins of PCOS hypothesis outlined in
Figure 1. Altered glucose homeostasis and excessive insu-
lin stimulation of ovarian follicles and oocytes may thus
provide further disruption of adult ovarian function and
oocyte development (see below).
In prenatally androgenized ewes, fetal testosterone excess
not only leads to polycystic ovarian morphology [13], but
also diminishes overall ovarian reserve and increases fol-
licular recruitment by accelerating follicle development to
primary through antral stages, thus depleting the propor-
tion of follicles remaining in the primordial pool [66]. If
such accelerated follicle recruitment continues into adult
life, without compensatory reduction in follicle atresia
[67] or an increase in postnatal follicle recruitment [68],
premature reproductive senescence will occur, as found in
three separate studies of prenatally androgenized animals
[50-52]. Recent studies have found follicular persistence
contributes toward the multifollicular morphology in pre-
natal testosterone-treated sheep [52]. Whether such ovar-
ian abnormalities are dependent on ovarian over-
stimulation by LH hypersecretion remains to be deter-
mined.
In prenatally androgenized female rhesus monkeys, con-
trolled ovarian hyperstimulation for IVF yields oocytes
deficient in developmental competence [28,69,70]. While
re-initiation of meiosis, maturation and fertilization
appear normal, oocytes from prenatally androgenized
females progress sub-normally during the early embry-
onic stages. Females monkeys exposed to androgen excess
during early gestation are particularly deficient and ferti-
lized oocytes progress to blastocyst at only 13% of the
numbers found in normal monkeys [28]. Intrafollicular
steroidogenic responses to gonadotropic stimulation are
also abnormal. Follicular fluid concentrations of andros-
tenedione and estradiol following recombinant human
(rh)FSH stimulation, alone, are diminished [69], while
intrafollicular progestogenic responses to combined
rhFSH stimulation followed by rhCG administration are
exaggerated [28]. Since androgens [21,30,71], estrogens
[72,73] and an appropriate progesterone to estradiol ratio
[74,75] all enhance oocyte development in primates, the
abnormal intrafollicular environment of prenatally
androgenized female monkeys may contribute to their
inferior oocyte quality. Dysregulation of LH and insulin
secretion in prenatally androgenized females may addi-
tionally contribute to oocyte impairments [28,70].
Fetal estrogen excess
The ovarian consequences of fetal estrogen excess are sur-
prisingly similar to those for fetal androgen excess [76],
suggesting that some components of androgen program-
ming may be mediated by conversion of testosterone to
estradiol. Since fetal female exposure to the non-aroma-
tizable androgen, DHT, however, induces anovulation
and LH hypersecretion in a similar manner to fetal testo-
sterone excess [53,56], direct androgen action in the
female fetus also re-programs adult reproductive function.
Exposure of non-primate female fetuses to diethyl-
stilbestrol (DES), a potent estrogen, results in anovulation
in adulthood [76], mainly through dysfunctional neu-
orendocrine regulation of hypothalamic GnRH release.
There also appear to be direct effects on the ovary. In
female mice exposed to DES during fetal life, adult ovar-
ian size is diminished, follicle numbers are reduced, there
is relative hyperplasia of ovarian stroma, and cultured
ovarian tissue is hyperandrogenic [14,77]. Transplanta-
tion of DES-exposed fetal ovaries under the kidney cap-
sule of ovariectomized, normal adult females fails to
normalize ovarian morphology, implicating a direct ovar-
ian effect of fetal estrogen excess programming [78]. Such
fetal estrogen excess in women induces moderate hyper-
androgenism [79], intermittent or absent menstrual cycles
and reduced fertility [15,80,81]. Not all studies, however,
find fetal DES-programmed ovarian abnormalities [82],
possibly due to reduced duration of fetal DES exposure.
Many of the estrogen-programmed ovarian abnormalities
appear to be mediated through DES binding to ERα [83].
Such ovarian impact of in utero estrogen excess suggests
that fetal exposure to environmental or dietary chemicals
that bind to estrogen receptors may result in similar re-
programming of ovarian function in adulthood [84,85].Reproductive Biology and Endocrinology 2006, 4:17 http://www.rbej.com/content/4/1/17
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In this latter regard, there is a potential fetal programming
link between in utero estrogen and androgen excess: expo-
sure of fetal rats to DES or to environmental toxicants with
estrogenic activity, such as bisphenol A, increases binding
activity at the androgen receptor [86]. Additionally, aro-
matization of androgen to estrogen may provide a crucial
step in direct fetal programming of ovarian function, since
fetal exposure to non-aromatizable DHT fails to induce
abnormal ovarian morphology in prenatally androgen-
ized ewe lambs [13].
Conclusion
Sufficient fetal estrogen, but not androgen, is crucial for
the normal development of oocytes and ovarian follicles.
Estrogen deficiencies lead to a reduced compliment of
oocytes and follicles, and abnormal ovarian function in
adulthood. When estrogen deficiency is complete, such as
in ArKO mice, partially masculinized ovaries develop pro-
viding a relatively new understanding of the role of estro-
gen in maintaining ovarian somatic cell phenotype. When
estrogen deficiencies are confined to fetal life, however, it
is not yet clear whether abnormalities manifest in adult-
hood. In contrast, discrete in utero excess of estrogen or
androgen results in abnormal programming of ovarian
function that includes anovulation and hyperandrogen-
ism. Such reproductive abnormalities appear to involve
both estrogenic and androgenic actions, since not all can
be explained in terms of aromatization of androgen to
estrogen. Fetal androgen excess, nevertheless, is the most
clinically relevant since it closely mimics the phenotype of
women with PCOS and implicates similar fetal perturba-
tions in the developmental origin of this common human
endocrine pathology.
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